A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies (DLB)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Nov 2022 Results assessing safety, pharmacokinetics, pharmacodynamics and biomarkers effects of the lowest effective dose of bosutinib in dementia with lewy bodies, presented at the 51st Annual meeting of the Society for Nueroscience.
18 Sep 2022 Results presented at the 26th International Congress of Parkinson's Disease and Movement Disorders
26 Apr 2022 Results assessing safety, biomarkers effects and determining the lowest effective dose of bosutinib presented at the 74th Annual Meeting of the American Academy of Neurology 2022

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com